First-ever approval of a CRISPR-based gene-editing therapy in the  U.S., Casgevy (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease

BOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Dec. 8, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the U.S. Food and Drug...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news